Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-controlled, Multicenter Phase III Trials (the ENHANCE Trials).

IF 21.7 1区 医学 Q1 CRITICAL CARE MEDICINE
Antonio Anzueto, Igor Z Barjaktarevic, Thomas M Siler, Tara Rheault, Thomas Bengtsson, Kathleen Rickard, Frank Sciurba
{"title":"Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-controlled, Multicenter Phase III Trials (the ENHANCE Trials).","authors":"Antonio Anzueto, Igor Z Barjaktarevic, Thomas M Siler, Tara Rheault, Thomas Bengtsson, Kathleen Rickard, Frank Sciurba","doi":"10.1164/rccm.202306-0944OC","DOIUrl":null,"url":null,"abstract":"<p><p><b>Rationale:</b> Ensifentrine is a novel, selective, dual phosphodiesterase (PDE)3 and PDE4 inhibitor with bronchodilator and antiinflammatory effects. Replicate phase III trials of nebulized ensifentrine were conducted (ENHANCE-1 and ENHANCE-2) to assess these effects in patients with chronic obstructive pulmonary disease (COPD). <b>Objectives:</b> To evaluate the efficacy of ensifentrine compared with placebo for lung function, symptoms, quality of life, and exacerbations in patients with COPD. <b>Methods:</b> These phase III, multicenter, randomized, double-blind, parallel-group, placebo-controlled trials were conducted between September 2020 and December 2022 at 250 research centers and pulmonology practices in 17 countries. Patients aged 40-80 years with moderate to severe symptomatic COPD were enrolled. <b>Measurements and Main Results:</b> Totals of 760 (ENHANCE-1) and 789 (ENHANCE-2) patients were randomized and treated, with 69% and 55% receiving concomitant long-acting muscarinic antagonists or long-acting β<sub>2</sub>-agonists, respectively. Post-bronchodilator FEV<sub>1</sub> percentage predicted values were 52% and 51% of predicted normal. Ensifentrine treatment significantly improved average FEV<sub>1</sub> area under the curve at 0-12 hours versus placebo (ENHANCE-1, 87 ml [95% confidence interval, 55, 119]; ENHANCE-2, 94 ml [65, 124]; both <i>P</i> < 0.001). Ensifentrine treatment significantly improved symptoms (Evaluating Respiratory Symptoms) and quality of life (St. George's Respiratory Questionnaire) versus placebo at Week 24 in ENHANCE-1 but not in ENHANCE-2. Ensifentrine treatment reduced the rate of moderate or severe exacerbations versus placebo over 24 weeks (ENHANCE-1, rate ratio, 0.64 [0.40, 1.00]; <i>P</i> = 0.050; ENHANCE-2, rate ratio, 0.57 [0.38, 0.87]; <i>P</i> = 0.009) and increased time to first exacerbation (ENHANCE-1, hazard ratio, 0.62 [0.39, 0.97]; <i>P</i> = 0.038; ENHANCE-2, hazard ratio, 0.58 [0.38, 0.87]; <i>P</i> = 0.009). Adverse event rates were similar to those for placebo. <b>Conclusions:</b> Ensifentrine significantly improved lung function in both trials, with results supporting exacerbation rate and risk reduction in a broad COPD population and in addition to other classes of maintenance therapies. Clinical trial registered with www.</p><p><strong>Clinicaltrials: </strong>gov and EudraCT (ENHANCE-1, www.</p><p><strong>Clinicaltrials: </strong>gov identifier NCT04535986, EudraCT identifier 2020-002086-34; ENHANCE-2, www.</p><p><strong>Clinicaltrials: </strong>gov identifier NCT04542057, EudraCT identifier 2020-002069-32).</p>","PeriodicalId":7664,"journal":{"name":"American journal of respiratory and critical care medicine","volume":"208 4","pages":"406-416"},"PeriodicalIF":21.7000,"publicationDate":"2023-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/11/79/rccm.202306-0944OC.PMC10449067.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of respiratory and critical care medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1164/rccm.202306-0944OC","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CRITICAL CARE MEDICINE","Score":null,"Total":0}
引用次数: 0

Abstract

Rationale: Ensifentrine is a novel, selective, dual phosphodiesterase (PDE)3 and PDE4 inhibitor with bronchodilator and antiinflammatory effects. Replicate phase III trials of nebulized ensifentrine were conducted (ENHANCE-1 and ENHANCE-2) to assess these effects in patients with chronic obstructive pulmonary disease (COPD). Objectives: To evaluate the efficacy of ensifentrine compared with placebo for lung function, symptoms, quality of life, and exacerbations in patients with COPD. Methods: These phase III, multicenter, randomized, double-blind, parallel-group, placebo-controlled trials were conducted between September 2020 and December 2022 at 250 research centers and pulmonology practices in 17 countries. Patients aged 40-80 years with moderate to severe symptomatic COPD were enrolled. Measurements and Main Results: Totals of 760 (ENHANCE-1) and 789 (ENHANCE-2) patients were randomized and treated, with 69% and 55% receiving concomitant long-acting muscarinic antagonists or long-acting β2-agonists, respectively. Post-bronchodilator FEV1 percentage predicted values were 52% and 51% of predicted normal. Ensifentrine treatment significantly improved average FEV1 area under the curve at 0-12 hours versus placebo (ENHANCE-1, 87 ml [95% confidence interval, 55, 119]; ENHANCE-2, 94 ml [65, 124]; both P < 0.001). Ensifentrine treatment significantly improved symptoms (Evaluating Respiratory Symptoms) and quality of life (St. George's Respiratory Questionnaire) versus placebo at Week 24 in ENHANCE-1 but not in ENHANCE-2. Ensifentrine treatment reduced the rate of moderate or severe exacerbations versus placebo over 24 weeks (ENHANCE-1, rate ratio, 0.64 [0.40, 1.00]; P = 0.050; ENHANCE-2, rate ratio, 0.57 [0.38, 0.87]; P = 0.009) and increased time to first exacerbation (ENHANCE-1, hazard ratio, 0.62 [0.39, 0.97]; P = 0.038; ENHANCE-2, hazard ratio, 0.58 [0.38, 0.87]; P = 0.009). Adverse event rates were similar to those for placebo. Conclusions: Ensifentrine significantly improved lung function in both trials, with results supporting exacerbation rate and risk reduction in a broad COPD population and in addition to other classes of maintenance therapies. Clinical trial registered with www.

Clinicaltrials: gov and EudraCT (ENHANCE-1, www.

Clinicaltrials: gov identifier NCT04535986, EudraCT identifier 2020-002086-34; ENHANCE-2, www.

Clinicaltrials: gov identifier NCT04542057, EudraCT identifier 2020-002069-32).

Abstract Image

Abstract Image

治疗慢性阻塞性肺病的新型磷酸二酯酶 3 和 4 抑制剂 Ensifentrine:随机、双盲、安慰剂对照、多中心 III 期试验(ENHANCE 试验)。
理由:恩西芬林是一种新型、选择性、双重磷酸二酯酶 (PDE)3 和 PDE4 抑制剂,具有支气管扩张和抗炎作用。为评估该药对慢性阻塞性肺病(COPD)患者的疗效,我们对雾化吸入的安非他酮进行了重复性 III 期试验(ENHANCE-1 和 ENHANCE-2)。研究目的评估安非他酮与安慰剂相比对慢性阻塞性肺病患者肺功能、症状、生活质量和病情加重的疗效。方法这些 III 期、多中心、随机、双盲、平行组、安慰剂对照试验于 2020 年 9 月至 2022 年 12 月期间在 17 个国家的 250 个研究中心和肺科诊所进行。患者年龄在 40-80 岁之间,患有中度至重度无症状慢性阻塞性肺病。测量和主要结果:共有760名(ENHANCE-1)和789名(ENHANCE-2)患者接受了随机治疗,其中分别有69%和55%的患者同时接受了长效毒蕈碱拮抗剂或长效β2-受体激动剂治疗。支气管扩张后的 FEV1 预测值分别为正常预测值的 52% 和 51%。与安慰剂相比,安非他酮治疗可显著改善0-12小时的平均FEV1曲线下面积(ENHANCE-1,87毫升[95%置信区间,55,119];ENHANCE-2,94毫升[65,124];两者的P P = 0.050;ENHANCE-2,比率比,0.57 [0.38,0.87];P = 0.009)和首次病情恶化时间延长(ENHANCE-1,危险比,0.62 [0.39,0.97];P = 0.038;ENHANCE-2,危险比,0.58 [0.38,0.87];P = 0.009)。不良事件发生率与安慰剂相似。结论在这两项试验中,安思芬特林都能明显改善肺功能,其结果支持在广泛的慢性阻塞性肺疾病人群中降低病情恶化率和风险,并可作为其他类别维持疗法的补充。临床试验已在 www.Clinicaltrials: gov 和 EudraCT 注册(ENHANCE-1,www.Clinicaltrials: gov 识别码 NCT04535986,EudraCT 识别码 2020-002086-34;ENHANCE-2,www.Clinicaltrials: gov 识别码 NCT04542057,EudraCT 识别码 2020-002069-32)。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
27.30
自引率
4.50%
发文量
1313
审稿时长
3-6 weeks
期刊介绍: The American Journal of Respiratory and Critical Care Medicine focuses on human biology and disease, as well as animal studies that contribute to the understanding of pathophysiology and treatment of diseases that affect the respiratory system and critically ill patients. Papers that are solely or predominantly based in cell and molecular biology are published in the companion journal, the American Journal of Respiratory Cell and Molecular Biology. The Journal also seeks to publish clinical trials and outstanding review articles on areas of interest in several forms. The State-of-the-Art review is a treatise usually covering a broad field that brings bench research to the bedside. Shorter reviews are published as Critical Care Perspectives or Pulmonary Perspectives. These are generally focused on a more limited area and advance a concerted opinion about care for a specific process. Concise Clinical Reviews provide an evidence-based synthesis of the literature pertaining to topics of fundamental importance to the practice of pulmonary, critical care, and sleep medicine. Images providing advances or unusual contributions to the field are published as Images in Pulmonary, Critical Care, Sleep Medicine and the Sciences. A recent trend and future direction of the Journal has been to include debates of a topical nature on issues of importance in pulmonary and critical care medicine and to the membership of the American Thoracic Society. Other recent changes have included encompassing works from the field of critical care medicine and the extension of the editorial governing of journal policy to colleagues outside of the United States of America. The focus and direction of the Journal is to establish an international forum for state-of-the-art respiratory and critical care medicine.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书